Decision: Favourable

Decisions Table

Study Title:

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

  • NREC Code:

    22-NREC-CT-177

  • Decision:

    Favourable

  • Meeting Date:

    07/12/2022

  • Study Type:

    CT application

  • Principal Investigator:

    Dr Jarushka Naidoo

  • PI Institution:

    Beaumont Hospital

  • Sponsor:

    AstraZeneca AB

Scroll to Top